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Background: Conventional bacterial stool culture is one of the more time-consuming tests in a routine clinical
microbiology laboratory. In addition, less than 5 % of stool cultures yield positive results. A molecular platform, the
BD MAX™ System (BD Diagnostics, Sparks, MD) offers the potential for significantly more rapid results and less
hands-on time. Time-motion analysis of the BD MAX Enteric Bacterial Panel (EBP) (BD Diagnostics, Quebec, Canada) on
the BD MAX System was compared to conventional stool culture in the microbiology laboratory of a tertiary care
pediatric hospital.
Methods: The process impact analysis of time-motion studies of conventional cultures were compared to those
of EBP with 86 stool specimens. Sample flow, hands-on time, processing steps, and overall turnaround time were
determined and analyzed. Data were obtained and analyzed from both standard operating procedures and direct
observation. A regression analysis was performed to ensure consistency of measurements. Time and process
measurements started when the specimens were logged into the accessioning area of the microbiology laboratory
and were completed when actionable results were generated.
Results: With conventional culture, negative culture results were available from 41:14:27 (hours:minutes:seconds)
to 54:17:19; with EBP, positive and negative results were available from 2:28:40 to 3:33:39.
Conclusions: This study supports the suggestion that use of the EBP to detect commonly encountered stool
pathogens can result in significant time savings and a shorter time-to-result for patients with acute bacterial diarrhea.
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The World Health Organization has reported that, world-
wide, there are nearly 1.7 billion cases of diarrheal disease
every year and that diarrheal disease is the second leading
cause of death in children under five years old [1, 2]. Each
year, diarrhea results in approximately 760,000 preventable
deaths of children under the age of five years. Diarrhea in
this age group is also a leading cause of malnutrition. Most
cases of this disease are related to unsafe drinking-water,
inadequate sanitation, and poor hygiene [1, 2].
Detection and identification of the etiological agents
of acute bacterial diarrhea are important for both the* Correspondence: joel.mortensen@cchmc.org
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unless otherwise stated.treatment of individual patients and for the manage-
ment of diarrheal diseases of public health importance.
Conventional bacterial culture remains the gold standard
for the aforementioned detection, even though stool cul-
ture has relatively low sensitivity and requires a significant
amount of labor. The use of nucleic acid amplification
methods to detect and identify the etiological agents of
acute bacterial diarrhea could have a significant impact on
the laboratory diagnostic process, clinical approach, and
epidemiology of this disease [3–5].
The objective of this study was to examine the labora-
tory impact of a new molecular platform (use of the BD
MAX Enteric Bacterial Panel on the BD MAX System)
on turnaround time, associated laboratory processes,
and the cost of providing results with this system com-
pared to conventional culture methods. Results of bothtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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assay for shiga-toxin) and the EBP, which include tests
for the detection of Salmonella spp., Shigella spp./
Enteroinvasive Escherichia coli (EIEC), Campylobacter
spp. (jejuni and coli), and Shiga toxin 1 and 2 genes in
stool specimens were evaluated. Lean and Six Sigma
processes were used to analyze the time from sample re-
ceipt to actionable result for conventional stool culture
and the EBP. The following “events or decisions per spe-
cimen” were determined: any action or thought process
that must occur to process and issue a result, the overall
distance traveled per sample as a measure of efficiency,
and the operating costs of the two systems [6].
(The results of this study were presented, in part, at
the 24th European Congress of Clinical Microbiology
and Infectious Diseases, Barcelona, Spain, May 10–13,
2014 and at the 114th General Meeting of the American
Society for Microbiology, Boston MA, May 17–20, 2014.)
Methods
Lean and Six Sigma processing analysis were performed
to evaluate time-to-results for both culture and EBP test-
ing. By design, this study did not involve human subjects
or any patient information. Observations were performed
without patient identifiers and additional testing was car-
ried out on discarded, anonymous samples. Any sample
ordered for routine stool culture was eligible for inclusion
in the study.
Culture
Clinical stool samples were immediately accessioned and
plated upon arrival in the laboratory following standard
laboratory practices. They were not stored prior to cul-
ture. Sample flow, hands-on time, processing steps, over-
all turnaround time, and specimen travel distance were
measured by two independent observers over the course
of three separate observation periods; each observation
period was five days. To eliminate any potential of
operator-to-operator bias during the study, 11 different
laboratory technologists were observed performing all
pre-analytical, analytical, and post-analytical culture
procedures which occurred at five different laboratory
stations: specimen receipt, specimen plating and incuba-
tion, culture reading, automated identification (Vitek 2
System, bioMérieux, Marcy l’Etoile, France) and shiga-
toxin testing (Immunocard STAT! EHEC, Meridian
Bioscience, Cincinnati, Ohio, USA).
In brief, for this study, stool samples that were submit-
ted for routine culture were transported in Cary Blair
Transport Medium (Meridian Bioscience, Inc.). Speci-
mens were processed within 2 h of receipt. Initially, sam-
ples were inoculated onto the following agar media: 5 %
sheep blood, MacConkey, Sorbitol MacConkey, Hek-
toen, Campy CVA (BD Diagnostics, Sparks, MD, USA).Cultures were incubated under standard conditions. Sus-
pected bacterial pathogens were identified using the
Vitek 2 System (bioMerieux) and standard conventional
methodologies as needed. Additional testing may have
included the following: Salmonella serotyping and Shigella
serotyping Becton, Dickinson and Company, Sparks, MD,
USA) and Remel RIM E. coli O157:H7 Latex Test (Remel,
Lenexa, KS, USA).
Additional data were obtained and analyzed from la-
boratory Standard Operating Procedures (SOP) used
routinely in this particular laboratory. In order to ensure
consistency during the study, a regression analysis of
measurements, processing, and adherence to the SOP
was performed. Correlation studies were performed on
independent data sets to ensure no bias was falsely in-
troduced by operator-to-operator performance [7]. The
following elements were analyzed: elapsed time, distance
traveled, processing steps performed, and clinical deci-
sions, from the time the specimens were logged into the
accessioning area until the time actionable results were
generated. Processing was observed and data were col-
lected during each of the following notable events: speci-
men arrival, specimen accessioning, specimen plating
and preparation, specimen incubation, first-day plate
reading and workup, subsequent day(s) reading, includ-
ing Campylobacter spp. cultures reading, automated
identification and additional workup, shiga-toxin broth
inoculation, shiga-toxin rapid testing, and verification of
results, and entering results into the laboratory/hospital
information system.
EBP testing
Methods similar to those used to evaluate culture pro-
cesses were measured and analyzed: elapsed time, dis-
tance traveled, processing steps, and clinical decisions
(also from the time specimens were logged into the
accessioning area to the time actionable results were
generated). Processing was observed and data were col-
lected during each of the following notable events: speci-
men arrival, specimen accessioning, control preparation,
specimen preparation, instrument preparation, worklist
preparation, instrument processing, and result verifica-
tion. For BD MAX testing, the samples were batched
and tested in different batch sizes. Batch sizes ranged
from 4 to 24 samples in increments of 4 to mimic rou-
tine clinical testing.
Cost analysis
Standard institutional cost analysis was used to deter-
mine the costs for conventional culture and for EBP.
The main cost components of the analysis were labor,
direct materials and supplies, and general shared costs
(Test Site Burden). Hands-on time (minutes) for each
step of the cultures and the EBP was multiplied by the
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mine labor costs. The quantity of each item and the cost
of each item used in culture and EBP testing were de-
rived from institutional inventory data. Institutional
overhead or Test Site Burden is the cost for basic ser-
vices such as lights and heat and the cost of common
shared laboratory equipment such as incubators, repeat
pipettes, etc.
Institutional review board
It was determined that this study did not meet regulatory
criteria for research involving human subjects because the
research did not obtain data through intervention or inter-
action with the individual or identifiable private informa-
tion. All observations of process were made without any
patient identifiers available to the observer. All specimens
tested on the BD MAX were anonymous, discarded sam-
ples that were only used after clinical testing was com-
pleted and for which no patient identifiers were used.
Results
86 patient specimens were examined. No pathogens under
consideration in this study (i.e., Salmonella, Campylobac-
ter, Shigella and shiga toxin producing organisms) were
detected by culture or BD MAX EBP.
To enable a comparison, simultaneously, 84 alternate
specimens tested by EBP were processed across six
batches of differing size (4 to 24 samples each) on the
BD MAX platform. Processing and turnaround times of
routine cultures were compared to the process and turn-
around times of EBP testing. The mean time to reportable
result for 86 routine cultures was 44:37:00 (hours:minutes:-
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Fig. 1 The mean turnaround time (TAT) to reportable results for 86 rou
Legend. *Represents 4 outlying culture results that required additional
negative for pathogenswere detected that required additional testing, the time to
final result ranged from 97:18:17 to 145:27:11.
Although the time to perform EBP testing is approxi-
mately two hours, EBP is designed and best used to
batch specimen testing at reasonable intervals as deter-
mined by each laboratory. If a reasonable operational
model is two EBP runs per day (one in the morning, one
in the afternoon), the time to reportable EBP results
would be, at most, 07:06:00 (no standard deviation; all
variability dependent upon batch size and timing of
run). Hands-on time per specimen was 0:01:30 (+/−
19 s). With an assumption of two EBP runs per day and
90 s hands-on time/specimen, there was an 85 % reduc-
tion of time to reportable results compared to culture.Process Steps for Culture and EBP
Technologists made an average of 141 and 25 decisions
per culture and EBP test, respectively. Thus, EBP testing
required 82 % fewer decisions than did culture (Table 1).
The number of steps and processes in each unique la-
boratory can be represented by a spaghetti diagram of
process flow for culture and for EBP testing (Fig. 2).Cost analysis
Detailed costs are listed in Table 2. The basic labor to
process and handle a stool culture was 0:15:00 – 0:17:00.
Approximately 20 % of the cultures required additional
process steps to rule out potential pathogens; these add-
itional steps resulted in additional labor (0:35:00 –
0:40:00) and supplies. The EBP required 0:01:28 hands
on time.MAX TAT (Hour)
7.10244
ur), MAX TAT (Hour)
tine stool cultures and 84 samples tested with BD MAX EBP.
testing for confirmation of the results. All final culture results were
Table 1 Average Number of Process Steps (Decisions/
Manipulations) Involved in Routine Culture and BD MAX EBP
Testing




Blood agar 43 -
MacConkey agar 26 -
Hektoen 26 -
Sorbitol MacConkey 14 -
Shiga toxin testing 4 -
Sample Preparation - 8
System operation - 13
Total activities 141 25
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A number of molecular platforms have been evaluated
for specific specimen types, including stool, and poten-
tial pathogens in clinical laboratory settings and have
been shown to be highly sensitive and specific when
compared to conventional methods [3–5]. The BD MAX
platform has been evaluated for the detection of MRSA
and more recently stool pathogens [8, 9]. Recently, severalFig. 2 Spaghetti Diagram of Process Flow for Routine Stool Culture (a) andinvestigators have recognized that beyond scientific valid-
ation, these platforms need to be evaluated for their im-
pact on the operations and the time to reportable results
in clinical laboratories [7, 10–12].
One of the more challenging parts of this study was
accounting for all of the costs. The lack of positive sam-
ples with target stool pathogens did not allow a complete
determination of the costs and labor associated with rou-
tine stool cultures. A community outbreak of acute bacter-
ial diarrhea might significantly impact both labor and
supplies for both of the methods in this study. In addition,
it was difficult to account for the individual variability
between technologists in the workup of stool cultures.
Differences in individual technologists and their experi-
ence could have affected the extent of work and supplies
needed for a culture. Nonetheless, including multiple
technologists in the performance of this study more ac-
curately represents real-world performance of the two
methods than, for example, performing the study with
specified research technologists. The use of a signifi-
cant amount of shared equipment for routine cultures
makes complete accounting for the portion of the cost
of equipment such as water baths, incubators, storage
rack, microscopes, etc. assigned to each culture diffi-
cult. At our institution, we use the somewhat arbitrary
“Test Site Burden” as one mechanism of sharing theseBD MAX EBP Testing (b)
Table 2 Cost Analysis of Routine Stool Cultures and BD MAX EBP Testing
Stool Culture EBP
Cost/Unit #Units Cost Cost/Unit #Units Cost
Basic test
Labor -Technologist time (minutes) 0.45 15 - 17 6.75 – 7.65 0.45 1.48 0.67
Information System labels 0.05 3 0.15 0.05 2 0.1
5 % Sheep Blood agar plate 0.25 1 0.25
MacConkey agar plate 0.25 1 0.25
Campy agar plate and BioBag 2.39 1 2.39
Hektoen Enteric agar plate 0.31 1 0.31
MacConkey Sorbitol agar plate 0.44 1 0.44
Shiga toxin test kit and MacConkey Broth 13.52 1 13.52
Disposable 10 μl loop 0.02 1 0.02
Enteric Panel Kit 30 – 35.00 1 30 – 35.00
MAX test cartridge 0.40 – 0.65 1 0.40 – 0.65
Test site burden 1.00 2 2.00 1.00 1 1.00
Additional workup*
Labor -Technologist time (minutes) 0.45 35-40 15.75 – 18.00
5 % Sheep Blood agar plate 0.25 1-3 0.25 – 0.75
Vitek-Gram negative ID card 6.00 1-3 6.00 – 18.00
RIM EC O157:H7 test 0.59 1 0.59
Total Cost (in $) $26.06 – 64.30 $32.19–37.44
*20 % of cultures required additional labor and supplies to rule out potential pathogens
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shift in supplies storage. A significant number of differ-
ent media and tests are need for routine cultures and
most of these require refrigerated storage. A move to the
EBP assay would reduce the number of tests and the
amount of media. In addition, adoption of the system
would shift much of that storage to room temperature.
In contrast to culture, the cost of operating the BD
MAX was more easily captured. However, there are sev-
eral additional issues that affect the cost of operating the
EBP assay that a clinical laboratory would need to con-
sider. Because of how the disposables are constructed,
samples can be run in various size batches. To optimize
and reduce cost, the ideal batch size is 24. To optimize
and reduce turnaround time, the ideal batch size is as
small as possible. Use of fewer stools samples per batch
would have a minor effect on the cost of the test. The
cost of the EBP would not change with a positive result;
however, a positive EBP would require a follow-up culture
to allow serotyping, antimicrobial susceptibility testing as
appropriate, and epidemiological studies, including time
and supplies to send isolates to the State Public Health La-
boratory. Depreciation of instruments is an important
consideration if the instrumentation is purchased outright.
Our analysis did not include the cost of the analyzer as
that cost per assay is directly related to the volume of as-
says performed on the instrument. Finally, the cost ofservice contracts is often not considered as part of the cost
of a test, but can represent a significant cost to the opera-
tions of the laboratory.
As clinical microbiology laboratories move from trad-
itional culture based methods to instrument based mo-
lecular methods, we need to look carefully at scientific
merits of the various options, but we need also to look
at the turnaround time of results, associated laboratory
processes, and the cost of providing results with this sys-
tem compared to conventional culture methods in our
laboratories.
Conclusion
This study supports the suggestion that use of the BD
MAX EBP can save significant time (over that required
by culture) in the laboratory diagnosis of acute bacterial
diarrhea caused by Salmonella spp., Shigella spp./(EIEC),
Campylobacter spp. (jejuni and coli), and Shiga toxin
producing E. coli which are responsible for 95 % of acute
bacterial gastroenteritis. The use of a flexible and fo-
cused approach to identifying enteric pathogens (bac-
teria, viruses & parasites) based on patient history or
risk, clinical presentation or clinician’s preference is
aligned with widely recommended clinical algorithms
which not only potentially streamline laboratory testing
and workflow in a cost effective manner, but also pro-
vide physicians with timely results which improve the
Mortensen et al. BMC Clinical Pathology  (2015) 15:9 Page 6 of 6standard of care for common causes of gastroenteritis.
As additional nucleic amplification assays become available,
the impact of the use of focused versus comprehensive
panels will continue to be evaluated for their respective
clinical relevance, cost and work flow implications.
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